# FormFactor: a real boom, priced for 2030 today FORM, NASDAQ. Published September 30, 2026. Price is the September 30, 2026 intraday quote, up 7.92% on the day. It is not a closing price. ## Verdict: REDUCE at $146.88 FormFactor is a better business than it was a year ago, with revenue up 32% and gross margin up almost 15 points, and the stock has answered by rising 286%. At $146.88 the price sits within 5% of my Bull value and asks today for revenue close to the company's own 2030 target. The buy zone starts at $63.18. - Bear value: $70.70 - Base value: $97.20 - Bull value: $139.90 - Downside to base value: -33.8% - Maximum buy price: $63.18 - Required margin of safety: 35% - Enterprise value / Base EBITDA: 38.2x - EBITDA implied by the price at 25x: about $454 million (Base $297 million) - Business quality: 79/100 - Valuation score: 24/100 - Confidence: 19/25, grade B FormFactor's revenue grew 31.9% in the second quarter, its non-GAAP gross margin gained 14.8 points in a year, and its stock is up 286% over twelve months. The first two numbers belong to the business. The third belongs to the market, and it is the one this analysis is about. At $146.88 on September 30, 2026, the shares trade 51.1% above my triangulated Base value of $97.20, a downside of 33.8%. The Bear value of $70.70 is 51.9% below the price and the Bull value of $139.90 is 4.8% below it, so even my optimistic case sits under today's quote. The framework's required margin of safety for this profile is 35%, which puts the maximum buy price at $63.18. The shares would have to fall about 57% to get there. The business deserves respect; the price asks for more than respect. Route: SF-13 Industrials and manufacturing, semiconductor test equipment. Economic classification: Quality Growth (8/12). Primary method: growth-adjusted EV/EBITDA on mid-cycle earnings. Secondary methods: forward P/E and free cash flow after stock-based compensation. Values are present fair value estimates, not 12 month price targets. The price is an intraday quote that moved 7.92% during the day. ## What FormFactor is FormFactor makes probe cards and test systems. A probe card is a precision board with thousands of microscopic needles that touches a chip while it is still on the silicon wafer and checks that it works before it is cut and packaged. Advanced chips for artificial intelligence, high bandwidth memory (HBM, the stacked memory next to AI processors) and advanced packaging need more test steps and more complex cards, which is why revenue is growing. Probe Cards were $209.7 million of the $258.2 million second-quarter revenue and Systems were $48.5 million. At its May 2026 investor day management set a target model for 2030: $1.6 billion of revenue, a 55% non-GAAP gross margin, operating expenses of 23% of revenue and $5.00 of non-GAAP earnings per share. It estimates the advanced probe card market will grow from about $2.8 billion to $4 billion by 2030. Co-packaged optics (CPO), which puts light-based connections next to the chip, is a new product line that management now expects to exceed $20 million of revenue in 2026. Concentration is material. According to the company's filings as summarized in the framework analysis, one customer was 22.9% of 2025 revenue, and three customers made up 17.1%, 16.9% and 12.9% of receivables at the end of the second quarter. ## The latest quarter | Q2 2026 (quarter ended June 27, 2026) | Result | | --- | --- | | Revenue | $258.2 million, up 31.9% year over year and 14.2% from Q1, $18.2 million above the midpoint of the outlook | | Gross margin | GAAP 50.7% (Q1: 38.4%, which included $21.5 million of restructuring in cost of revenue), non-GAAP 53.3% (a year earlier: 38.5%) | | Operating income | GAAP $57.8 million (a year earlier: $12.3 million), non-GAAP $72.0 million | | Earnings per share | GAAP $0.71 (a year earlier: $0.12), non-GAAP $0.82 (a year earlier: $0.27) | | Cash flow | Operating cash flow $61.8 million, capital spending $9.6 million, company-defined free cash flow $52.6 million | | First half | Revenue $484.4 million (+31.9%), operating cash flow $106.8 million, capital spending $24.8 million, stock-based compensation $16.7 million | | Liquidity | $345.6 million of cash and marketable securities against about $11.6 million of debt | | Q3 outlook | Revenue $270 million plus or minus $10 million, non-GAAP gross margin 54% plus or minus 1.5 points, non-GAAP EPS $0.86 plus or minus $0.09, non-GAAP operating expenses $70 million including about $7 million of pre-production costs for the new Texas factory | The quarter was excellent by any measure, and management has beaten its own outlook in every recent quarter. One caution comes from management itself: the chief financial officer described a gross margin of about 51% as the sustainable baseline at current volumes and mix, below the 53.3% just reported. ## Why earnings and free cash flow cannot simply be annualized FormFactor is a cyclical manufacturer, so I value it on mid-cycle EBITDA (earnings before interest, taxes, depreciation and amortization) and on free cash flow after stock-based compensation (SBC), not on the best quarter multiplied by four. First half free cash flow was $82.0 million by my simple measure (operating cash flow minus capital spending). After deducting $16.7 million of SBC, a real cost paid in shares, the hard figure is **$65.3 million, or 79.6% of the headline**. That first-half figure cannot be doubled. Management expects 2026 cash capital spending of $140 million to $170 million for the Farmers Branch, Texas factory, of which only $24.8 million was spent in the first half. The second half therefore carries roughly $115 million to $145 million of capital spending, before a $24.2 million state grant that partly offsets it. My normalized scenarios are revenue of $1.00 billion, $1.10 billion and $1.20 billion with EBITDA margins of 23%, 27% and 30%. That gives EBITDA of **$230 million** in the Bear case, **$297 million** in the Base case and **$360 million** in the Bull case, and hard free cash flow of $145 million, $200 million and $260 million. For perspective, my estimate of second-quarter EBITDA after SBC and before restructuring is about $71.5 million, or $286 million annualized, so the Base case asks for little beyond today's run rate. Trailing twelve month EBITDA was $187 million (S&P Global). The problem is not the Base earnings. It is the multiple they must carry. ## Balance sheet and shares The balance sheet is excellent. Cash and marketable securities of $345.6 million less about $11.6 million of debt gives net liquidity of roughly $334 million. That is still only 2.9% of the $11.7 billion market value, so it cushions the business without changing the valuation much. The share count is moving the wrong way. Diluted shares were 79.6 million in the second quarter against 77.5 million a year earlier, an increase of 2.7%. FormFactor did not repurchase any shares in the first half of 2026 (it spent $24.6 million in the first half of 2025) and paid $16.0 million in taxes on employee share awards. About $70.9 million remains under the buyback authorization. I use 79.6 million diluted shares for all per share values. ## Primary valuation: growth-adjusted EV/EBITDA Enterprise value (EV) is market value plus debt minus cash. The primary method builds a justified EV/EBITDA multiple: a standard industrial anchor of 16x, plus 6x for structural growth, 2x for the balance sheet and 2x for the moat, minus 2x for cyclicality and customer concentration and 1x for dilution and execution risk. The result is a Base multiple of about **23x**. | Case | EBITDA | EV/EBITDA | Value per share | | --- | --- | --- | --- | | Bear | $230 million | 23x | $70.65 | | Base, bridge multiple | $297 million | 23x | $90.01 | | Base, scenario multiple | $297 million | 26x | $101.21 | | Bull | $360 million | 30x | $139.87 | Each value is EBITDA times the multiple, plus $334 million of net liquidity, divided by 79.6 million shares. The first draft used two different Base multiples, 23x in the bridge and 26x in the scenario table. I use the midpoint, so the **primary Base is $95.60**. The Bear case keeps the same 23x multiple, because trough earnings in this industry often arrive together with a higher multiple. ### Sensitivity: value per share | EBITDA \ EV/EBITDA | 22x | 26x | 30x | | --- | --- | --- | --- | | $250 million | $73.3 | $85.9 | $98.4 | | $300 million | $87.1 | $102.2 | $117.3 | | $350 million | $100.9 | $118.5 | $136.1 | No cell in the table reaches today's price. ## Secondary valuation: forward P/E and hard free cash flow | Method | Bear | Base | Bull | | --- | --- | --- | --- | | 2027 EPS of about $3.75 at 22x, 28x, 34x | $82.50 | $105.00 | $127.50 | | Hard free cash flow of $200 million ($2.51 a share) at 30x to 35x | | $75.40 to $87.90 | | The 2027 earnings per share figure is a consensus estimate taken from the framework's source register, not company guidance. The **secondary Base is $105.00**. The free cash flow check is lower, which shows how much of today's price is a premium for growth that has not yet happened. ## Historical cross-check On trailing figures the shares are expensive against their own history. Enterprise value is about 61 times trailing twelve month EBITDA of $187 million (S&P Global) and about 13 times trailing revenue. One data provider puts the five-year average price to sales ratio near 4.8x, so the stock now trades at more than two and a half times that level. Price to book is about 10.5x. The framework analysis also cites a five-year EV/EBITDA reference of about 25.5x, which I could not confirm independently and do not rely on. The consensus price target of $138.63 (10 analysts, StockAnalysis) is 5.9% below the current price. ## Valuation triangulation | Method | Base value | Weight | | --- | --- | --- | | Primary EV/EBITDA (midpoint of 23x and 26x) | $95.60 | 50% | | Forward P/E | $105.00 | 30% | | Hard free cash flow check (midpoint) | $81.70 | 10% | | Historical check (midpoint of the framework's $90 to $105) | $97.50 | 10% | | Triangulated Base | $97.20 | 100% | The primary and secondary methods differ by about 9%, well under the 20% warning threshold. The first draft's stated weights of 50%, 30% and 20% cannot produce its $102 Base from its own table; they produce between $95.70 and $98.80 depending on how the last 20% is filled. I split it evenly between the cash flow and historical checks, which gives $97.20. The Bear ($70.70) and Bull ($139.90) are the EBITDA scenario values, without the rounding the first draft applied. ## What is the market already pricing in? At $146.88 and 79.6 million diluted shares, market value is about $11.69 billion and enterprise value about $11.36 billion, or **38.2x Base EBITDA**. At a still generous 25x multiple the price requires EBITDA of about **$454 million**, 53% above the Base. At a 30% EBITDA margin that means roughly $1.51 billion of revenue, or 95% of management's $1.6 billion target for 2030, four years early. Even at the Bull multiple of 30x the price needs $379 million of EBITDA, more than my Bull case of $360 million. Put another way, the stock trades at 29 times the $5.00 of earnings per share management hopes to reach in 2030. The market is capitalizing the finished plan today. ## Bear, base and bull scenarios | | Bear | Base | Bull | | --- | --- | --- | --- | | Main assumptions | Revenue of $1.00 billion, 23% EBITDA margin, AI test demand cools | Revenue of $1.10 billion, 27% margin, growth holds but 2026 proves close to a peak | Revenue of $1.20 billion, 30% margin, structural growth and a premium multiple persist | | EBITDA | $230 million | $297 million | $360 million | | Value per share | $70.70 | $97.20 | $139.90 | | Versus $146.88 | -51.9% | -33.8% | -4.8% | I assign no probabilities to the scenarios. All three values sit below the price. The price is reachable only if FormFactor beats my Bull case, and beating it in every way at once is what the price assumes. ## How the buy price is set A Confidence B score carries a base margin of safety (MOS) of 30%. I add 5 points for semiconductor cyclicality and 5 points for customer concentration, and subtract 5 points for the net cash balance sheet, which gives a required MOS of **35%**. Applied to the $97.20 Base, the **maximum buy price is $63.18**, and a stronger 45% margin marks a strong-buy reference near $53.46. The net cash credit is generous, since cash is under 3% of the company's value; without it the required margin would be 40% and the maximum buy price $58.32. The shares would need to fall about 57% from $146.88 to reach $63.18. ## Dividend and capital return FormFactor pays no dividend, so the income check does not apply. Buybacks have been intended to offset share issuance and none were made in the first half, while diluted shares rose 2.7%. ## Reasons to own FORM - **Genuine test intensity growth.** HBM, advanced packaging and custom AI chips raise the number and complexity of test steps, and FormFactor has a place in each. - **Operating leverage is real.** Revenue is up 32% year over year, non-GAAP gross margin is up 14.8 points and non-GAAP earnings per share tripled to $0.82. - **A real moat.** Qualification barriers, precision manufacturing, patents and customer co-development make probe cards difficult to switch. - **A net cash balance sheet.** About $334 million of net liquidity funds the Texas expansion without borrowing. - **A consistent record of beating guidance.** Q2 revenue came in $18.2 million above the midpoint of the outlook. ## What could go wrong? - **Thesis breaker: valuation.** Strong execution can still produce poor stock returns if a premium multiple normalizes. The stock is up 28% since its September 11 close of $114.95. - **Customer concentration.** A design loss, a second-source decision or an in-house test program at a large customer could take a large share of revenue. - **Semiconductor cyclicality.** Strength in HBM and high-performance computing does not remove inventory, utilization and capital spending cycles. FormFactor's revenue was nearly flat in 2025 ($785.0 million against $763.6 million) before this surge. - **Capacity ramp.** Farmers Branch starts production late in the fourth quarter, ramps through 2027 and is expected to reach initial target capacity by early 2028. Cash capital spending of $140 million to $170 million in 2026 and pre-production costs of $25 million to $30 million come first. - **Gross margin may have peaked for now.** Management calls about 51% the sustainable baseline at current volumes, and the 2030 target of 55% depends on the new factory. - **Dilution.** Diluted shares rose 2.7% in a year and no buybacks were made in the first half. ## Management execution Management has beaten its outlook on revenue, gross margin and earnings per share in each recent quarter, posted three consecutive record quarters, set measurable 2030 targets and restructured manufacturing to lower cost. The offsets are a capacity ramp that must be delivered on time, long-dated targets and a rising share count. **Assessment: 16/20, good. The next test is whether gross margin holds above the 51% baseline once volumes normalize.** ## Stock Analyza scorecard | Economic classification | Score | | --- | --- | | Normalized return on invested capital | 1/2 | | Revenue growth, multi-year | 1/2 | | Free cash flow per share growth | 1/2 | | Balance sheet | 1/1 | | Unit economics | 1/1 | | Recurring and repeat economics | 1/2 | | Reinvestment runway | 2/2 | | Total: Quality Growth | 8/12 | Compounder status is withheld because return on capital and free cash flow per share are not yet consistently exceptional through a full cycle. Business quality is **79/100**: moat and pricing power 17/20, return versus cost of capital 13/20, balance sheet 15/15, earnings and cash quality 11/15, growth and runway 13/15, management and capital allocation 7/10, dilution and governance 3/5. The valuation score is **24/100**: discount to Base 0/40, protection against the Bear case 0/20, agreement between methods 13/15, historical valuation 2/10, reverse valuation 4/10, data quality 5/5. ## Confidence score | Confidence | Score | | --- | --- | | Data quality / source provenance | 4/5 | | Predictability | 3/5 | | Valuation robustness | 4/5 | | Accounting transparency | 5/5 | | Scenario dispersion | 3/5 | | Total | 19/25, grade B | Reporting is clear and the methods agree. Predictability and scenario dispersion are marked down because semiconductor cycles, customer concentration and a very fast change in earnings make the range of outcomes wide. ## What I would watch from here ### Green - Revenue growth above 15% - Non-GAAP gross margin at or above 52% - HBM and DRAM momentum growing, Foundry and Logic growing above 10% - Hard free cash flow above 75% of headline - Diluted share growth at or below 0.5% - Net liquidity above $250 million - Customer concentration declining - 2030 revenue and gross margin trajectory on or ahead of plan ### Yellow - Revenue growth 5% to 15% - Non-GAAP gross margin 48% to 52% - HBM and DRAM flat, Foundry and Logic growing up to 10% - Hard free cash flow 60% to 75% of headline - Diluted share growth 0.5% to 2% - Net liquidity $100 million to $250 million - Customer concentration stable - 2030 targets slipping modestly ### Red - Revenue growth below 5%, or a decline - Non-GAAP gross margin below 48% - A material decline in HBM or DRAM, or a fall in Foundry and Logic - Hard free cash flow below 60% of headline - Diluted share growth persistently above 2% - Net liquidity below $100 million - Customer concentration rising materially - A structural miss on the 2030 targets Today's readings are green on revenue growth (31.9%), gross margin (53.3%), hard cash conversion (about 80%) and net liquidity ($334 million). Dilution (2.7%) is in the red zone and customer concentration is high. Review with the third-quarter report, expected around October 28, 2026. ## The three most important thesis breakers 1. The loss of a major customer or design, or a move to second sourcing or in-house test. 2. A reversal in HBM or high-performance computing demand before the valuation premium is earned. 3. Failure to sustain margin improvement while capacity spending and dilution rise. ## Adversarial review The first draft's arithmetic on its own inputs was mostly clean: the first-half free cash flow, net liquidity, scenario values, sensitivity grid and the implied multiples all reconcile. The corrections came in the triangulation, the rounding and the price. | Item | First draft | Corrected | | --- | --- | --- | | Base value | $102, which its 50/30/20 weights and layer table do not reproduce | $97.20 from explicit weights (range $95.70 to $98.80 depending on the last 20%) | | Bear value | $72, rounded up from $70.65 | $70.70 | | Bull value | $138, rounded down from $139.87 | $139.90 | | Maximum buy price | $66.30 (35% off $102) | $63.18 (35% off $97.20) | | Price and downside | $148.71 intraday, unconfirmed, downside 31.4% | $146.88 intraday quote on September 30, downside 33.8% | | Base multiple | 23x in the bridge, 26x in the scenario table | Midpoint used, inconsistency stated | | Free cash flow | First-half figure $81.97 million (operating cash flow minus capital spending) | Kept; the company's own definition gives $83.28 million, so the difference is small | | Historical EV/EBITDA | A five-year reference of 25.5x | Could not be confirmed, replaced with trailing multiples and a price to sales comparison | | New context | Capital spending timing, Q3 cost outlook, no buybacks, the 51% baseline margin | Added to the quarter, risks and capital sections | None of these corrections changes the Reduce verdict. They reduce the Base value by $4.80 and the maximum buy price by $3.12, and they remove rounding that had moved the Bear up and the Bull down. The strongest counter-thesis, for the bulls: HBM, advanced packaging, custom accelerators and co-packaged optics could turn FormFactor from a cyclical equipment vendor into a structural enabler with higher growth and higher margins. If revenue passes $1.6 billion before 2030, EBITDA margin exceeds 30% and the customer base broadens, a multiple of 30x or more could be defended. The response is that this is possible and sits in my Bull case, but the price already requires economics close to the 2030 target under a premium multiple, so the return depends on beating the target, not meeting it. | Robustness check | Result | | --- | --- | | $300 million EBITDA at 26x (consensus-centered) | $102.2 | | $300 million EBITDA at 22x | $87.1 | | $350 million EBITDA at 30x (generous) | $136.1 | | $400 million EBITDA at 30x (very generous) | $154.9, the first case that reaches the price | | 2030 target: $1.6 billion revenue, 30% margin, 25x | $154.9 before any discount for the four years of waiting | | Hard free cash flow cross-check | $75.40 to $87.90 | | Required margin of safety without the net cash credit | 40%, maximum buy price $58.32 | Audit flags: the EBITDA scenarios, the justified multiple bridge and the 2027 EPS consensus are estimates, not company guidance. The customer concentration percentages come from the framework analysis and I did not reopen the filing tables. My estimate of quarterly EBITDA after SBC is approximate because depreciation is taken as half of the six-month figure. The reference price is an intraday quote that moved 7.92% during the day. The publication gate status is PASS WITH WARNING because forward growth and margin assumptions remain structurally uncertain and because of the intraday price. ## Final verdict: reduce at $146.88 FormFactor is a high-quality manufacturer whose growth inflection is real. Its shares, though, have risen 286% in a year and now trade above my Bear and Base values and within 5% of my Bull value. At $146.88 a buyer is paying today for the company management hopes to be in 2030, with the $5.00 earnings target already priced at 29 times. **Verdict: REDUCE at $146.88. Triangulated Base value $97.20, downside 33.8%, Confidence B (19/25). Required margin of safety 35%, maximum buy price $63.18.** The case changes if the price falls toward the buy zone with the business still executing, or if the third-quarter and fourth-quarter reports show revenue and margins well above my Bull case. ## More analyses on Patreon This analysis is free. Premium members get every in-depth analysis, the full archive and a vote on which stocks get analyzed next: https://www.patreon.com/stockanalyza ## Sources Primary sources include FormFactor's second-quarter 2026 earnings release and Form 10-Q (quarter ended June 27, 2026), its first-quarter 2026 and fourth-quarter 2025 releases, the second-quarter and first-quarter earnings calls, the May 2026 investor day materials and the 2026 proxy statement. Market data comes from StockAnalysis (S&P Global Market Intelligence) and Equibles. Consensus estimates come from public aggregators cited in the framework analysis. The reference market price is $146.88, the September 30, 2026 intraday quote from the XTB trading app, up 7.92% on the day. The last confirmed close was $136.25 on September 29, 2026. Balance sheet and cash flow figures are as of June 27, 2026. Normalized EBITDA, scenario values and the justified multiple are analytical estimates, not company guidance. **Disclaimer.** This analysis is provided solely for research and educational purposes. It is not personalized investment, financial, legal or tax advice. FormFactor is exposed to the semiconductor cycle, to customer concentration and to the execution of a large capacity expansion, and its shares are volatile. Investors can lose part or all of their invested capital. Framework: SF-13 Industrial and Manufacturing, semiconductor test equipment. Economic class: Quality Growth. Engine: growth-adjusted EV/EBITDA. Confidence: B/19. Data status: PASS WITH WARNING. Adversarial gate: PASS WITH WARNING. Version: Master v3.1.